FGFR1 and squamous cell lung carcinoma: Therefore, we performed an in-depth genomic characterization of 16 FGFR1-amplified cell lines and PDX models with a known in vitro and in vivo response to FGFR inhibition, and 26 additional FGFR1-amplified squamous cell lung carcinoma samples from patients with an unknown response to FGFR inhibition (Figure 1A).